Ceftazidime Sodium
The sodium salt form of ceftazidime, prepared for intravenous or intramuscular injection to treat serious gram-negative infections. It shares the anti-Pseudomonal coverage of the parent drug and is commonly used in intensive care settings. When used in combination with avibactam, it extends coverage to carbapenem-resistant Enterobacteriaceae.
Moleküler Ağırlık
568,6000 g/mol
TPSA
248,00 Ų
Terapötik Alanlar
Etki Mekanizması
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
2D Yapı
Cite this structure
Embed this structure
SMILES
CC(C)(O/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccccc3)CS[C@H]12)c1csc(N)n1)C(=O)[O-].[Na+]
InChI
InChI=1S/C22H22N6O7S2.Na/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27;/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34);/q;+1/p-1/b26-13-;/t14-,18-;/m1./s1
Molecular Formula
C22H21N6NaO7S2
HBD / HBA
2 / 12
Döndürülebilir Bağlar
7
Ağır Atomlar
38
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
The sodium salt form of ceftazidime, prepared for intravenous or intramuscular injection to treat serious gram-negative infections. It shares the anti-Pseudomonal coverage of the parent drug and is commonly used in intensive care settings. When used in combination with avibactam, it extends coverage to carbapenem-resistant Enterobacteriaceae.
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Yes, Ceftazidime Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200768. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5488543. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="ceftazidime-sodium"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/ceftazidime-sodium/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/ceftazidime-sodium/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/ceftazidime-sodium/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="ceftazidime-sodium"></drugfyi-drug>